Renowned autoimmune expert Georg Schett launches biotech venture focused on antibody therapies
German researcher Georg Schett has co-founded a biotech company that will pursue antibody-based treatments for autoimmune disease, not CAR-T therapy.
Over the past five years Schett has become a leading figure in autoimmune research, showing that CAR-T can reprogram immune systems. He now joins a startup as a co-founder, but the new firm will concentrate on antibody therapies rather than CAR-T. The move adds another advisory role to his portfolio of several biotech boards.
Why it matters
The new company could accelerate antibody-based drugs for autoimmune patients, offering alternatives to current therapies.
In this story
Georg Schettautoimmune diseaseantibody therapybiotech startupCAR-Timmune system resetGerman researcher